UiPath (PATH) News Today

UiPath Inc. (NYSE:PATH) is seeing mixed analyst activity and strategic developments that are driving investor sentiment. Several firms have raised price targets or issued positive forecasts, while others have maintained cautious ratings. The stock’s recent volatility reflects these varied signals.

• Morgan Stanley lifted its price target on PATH to $15.00 (from $12.00) with an “equal weight” rating, implying roughly 20% upside.
• Canaccord Genuity boosted its objective to $16.00 (from $14.00) and reiterated a “buy” rating, signaling strong confidence in growth prospects.
• UiPath and HCLTech formed a strategic partnership to accelerate agentic automation for global enterprises, expanding UiPath’s market reach.
• Bank of America raised its PATH target to $12.00 (from $10.00), reflecting improving execution trends.
• Barclays increased its price target to $14.00, reinforcing its upbeat view on UiPath’s platform traction.
• Truist Financial issued a forecast for strong price appreciation, highlighting UiPath’s enterprise automation momentum.
• Evercore ISI assigned a new $15.00 price target, underlining high conviction in UiPath’s long-term growth.
• Wells Fargo set a $12.00 target, aligning with broader analyst optimism on UiPath’s scalability.
• Royal Bank of Canada issued a positive forecast for PATH, citing robust demand for AI-driven automation.
• Scotiabank raised its target to $13.00, reflecting stronger-than-expected Q1 indicators.
• Shares gapped up after UiPath reported strong earnings, underscoring solid execution in Q1 FY2026.
• BofA maintained an “underperform” rating on PATH despite raising its target to $12.00, pointing to near-term execution improvements but lingering valuation concerns.
• Zacks highlighted PATH as one of the most-watched stocks, indicating heightened investor attention without a clear directional bias.
• DA Davidson reiterated a “neutral” rating with a $14.00 target and forecasted Q2 EPS of –$0.07, reflecting ongoing investment in growth.
• Needham & Company reiterated its “hold” rating, suggesting investors await further operational milestones.
• PATH shares traded down about 5% following these mixed signals, reflecting short-term profit-taking and market volatility.